Cemiplimab Addition to Docetaxel and Ramucirumab Trial in NSCLC
Adding cemiplimab to docetaxel and ramucirumab may increase tumor cell death compared with docetaxel and ramucirumab alone in patients with stage IV or recurrent non‑small cell lung cancer.
This page lists ongoing lung cancer clinical trials at UC Davis, detailing various investigational therapies targeting EGFR, KRAS, and immunotherapies with phase II/III designs.
Access to contemporary clinical trial information enables patients and clinicians to identify emerging therapies that may improve outcomes for lung cancer.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT